期刊文献+

紫杉醇对人肝癌细胞株MHCC97-H的细胞形态和周期的影响

Effects of paclitaxel on cellular morphous and cell cycle of human hepatoma carcinoma cell strain MHCC97-H
下载PDF
导出
摘要 目的研究紫杉醇对体外培养肝癌细胞MHCC97-H的细胞形态和细胞周期的影响,初步探讨其作用机制。方法 (1)将MHCC97-H传代培养后,给予不同浓度的紫杉醇作用24 h,透射电镜观察细胞形态特征;(2)不同浓度的紫杉醇分别作用MHCC97-H 12、24、48 h后,MTT法检测肝癌细胞的抑制率,并绘制药物浓度-细胞抑制率曲线;(3)不同浓度的紫杉醇作用MHCC97-H 48 h后,用流式细胞仪测定细胞周期的变化及凋亡情况。结果 (1)随着紫杉醇浓度的提高,MHCC97-H的细胞伪足数量减少;(2)紫杉醇对体外培养的MHCC97-H生长具有明显抑制作用,并且存在剂量与时间依赖性;(3)紫杉醇可以将MHCC97-H阻滞于G2-M期,并促进其凋亡。结论紫杉醇可以将MHCC97-H大部分阻滞于G2-M期,并通过诱导肝癌细胞凋亡来协同发挥抗癌作用,同时使肝癌细胞伪足减少来降低其运动能力。紫杉醇可能是有潜力的抗肝癌生长及转移的药物。 Objective To investigate the effects of paclitaxel on the cellular morphous and cycle of hepatoma carcinoma cell MHCC97 - H which was cultured in vitro, and to discuss its mechanism of action. Methods ( 1 ) After the serial subeultivation of MHCC97 - H, different concentrations of paclitaxel were used to treat the cells for 24 h. Transmission electron microscope was used to observe the cellular morphologic characteristics. (2)After the treatment of MHCC97 - H with different concentrations of paclitaxel for 12,24, and 48 h, MTY assay was used to detect the inhibition ratio of hepatoma carcinoma cell, and the drug concentration - cellular inhibition rate curve was drawn. ( 3 ) After the treatment of MHCC97 - H by different concentrations of paclitaxel for 48 h ,flow cytometry was used to detect the changes of cell cycle and apoptosis. Results ( 1 ) Along with the increase of paclitaxel concentration, the pseudopodium amount of MHCC97 - H cell decreased. (2) Paelitaxel had significant inhibitive effect on the growth of MHCC97 - H in vitro,and there was a dose - time dependence. (3)Paelitaxel could arrest MHCC97 - H cell within the G2 - M phase and induce the apoptosis. Conclusion Paclitaxel can arrest most of the MHCC97 - H cells within the G2 - M phase. It has the effect of anti - tumor through reducing the apoptosis of hepatoma carcinoma cells and reduces the pseudopodium amount of carcinoma cell to decrease the moving ability of MHCC97 - H cell. Therefore,it is a potential drug of anti - growth and anti - metastasis of hepatic cancer.
出处 《西南国防医药》 CAS 2012年第8期823-826,共4页 Medical Journal of National Defending Forces in Southwest China
关键词 紫杉醇 肝癌 抑制率 凋亡 转移 paclitaxel hepatic cancer inhibition ratio apoptosis metastasis
  • 相关文献

参考文献3

二级参考文献17

  • 1Desmond Yip 1, Michael Findlay 2, Michael Boyer 1 and Martin H. Tattersall 3.Hepatocellular carcinoma in central Sydney :a 10yearreview of patients seen in a medical oncology department[J].World Journal of Gastroenterology,1999,5(6):483-487. 被引量:17
  • 2Rigas JR.Non-platinum based combination chemotherapy:phase Ⅰ and Ⅱ trials of docetaxel plus gemcitabine,vinorelbinge,or irinotecan[J].Semina in Oncology,2001 ;28(9):15 ~ 20
  • 3Langer CJ.Advanced non-small cell lung carcinoma:the emerging role of docetaxel[J].Invest New Drugs,2000; 18 (1):17 ~ 28
  • 4Vaishampayan U,Parchment RE,Jasti BR,et al.An overview of the pharmacokinetics and pharmacodynamics[J].Urology,1999;54(6):22~29
  • 5Pronk LC,Stoter G,Verweij J.Docetaxel:single agent activity,development of combination treatment and reducing side-effects[J].Cancer Treatment Review,1995; 21 (5):463 ~ 478
  • 6Pradier O,Rave-Frank M,Lehmann J,et al.Effects of docetaxel in combination with radiation on human head and neck cancer cells and cervical squamous cell carcinoma cells[J].Int J Cancer,2001; 91 (6):840 ~ 845
  • 7Koukourakis MI,Bahlitzanakis N,Froudrakis M,et al.Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage Ⅲ b non-small-cell lung cancer[J].Bri J Cancer,1999;80(11):1792 ~ 1796
  • 8Wu HG,Bang YJ,Choi EK,et al.Phase Ⅰ study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage Ⅲ nonsmall-cell lung cancer[J].Int J Radiat Oncol Biol Phys,2002;52(1):75 ~ 80
  • 9Choy H,DeVore RF,Hande KR,et al.Phase Ⅰ trial of outpatient weekly docetaxel,carboplatin and concurrent thoracic radiation therapyfor stage Ⅲ unresectable non-small-cell lung cancer:a Vanderbilt cancer center affiliate network (VCCAN) trial[J].Lung Cancer,2001 ;34(3):441 ~ 449
  • 10George Fountzilas,Dimitrios Pectasides,Anna Kalogera-Fountzila,Dimosthenis Skarlos,Haralambos P. Kalofonos,Christos Papadimitriou,Dimitrios Bafaloukos,Stefanos Lambropoulos,Savvas Papadopoulos,Helen Kourea,Christos Markopoulos,Helen Linardou,Dimitrios Mavroudis,Evangelos Briasoulis,Nicholaos Pavlidis,Evangelia Razis,Paraskevas Kosmidis,Helen Gogas.Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group[J].Breast Cancer Research and Treatment.2005(1)

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部